These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 3927468

  • 21. R-(-)-deprenyl and parkinsonism.
    Yahr MD.
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [Abstract] [Full Text] [Related]

  • 22. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N, Damase-Michel C, Senard JM, Rascol O, Montastruc JL.
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [Abstract] [Full Text] [Related]

  • 23. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK.
    J Neural Transm Suppl; 1987 May; 25():149-55. PubMed ID: 3123601
    [Abstract] [Full Text] [Related]

  • 24. [Drug therapy of Parkinson's disease].
    Myllylä V.
    Duodecim; 1997 May; 113(18):1827-34. PubMed ID: 10892076
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Current controversies in the use of selegiline hydrochloride.
    Lees AJ.
    J Neural Transm Suppl; 1987 May; 25():157-62. PubMed ID: 3123602
    [Abstract] [Full Text] [Related]

  • 29. Treatment of Parkinson's disease.
    Lieberman A.
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH, Myllylä V.
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M.
    J Neural Transm Suppl; 1986 Jul; 22():107-15. PubMed ID: 3097254
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. MAO-B inhibitors in Parkinson's disease.
    Olanow CW.
    Adv Neurol; 1993 Jul; 60():666-71. PubMed ID: 8420207
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ.
    BMJ; 1995 Dec 16; 311(7020):1602-7. PubMed ID: 8555803
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.